CD8A and cancer: Lastly, our proof-of-principle analysis focuses solely on TNBC and should not be interpreted in the context of other cancers, however, we note that the role of effector CD8+ T cells in mediating outcomes has been well documented across numerous cancer types, suggesting that opioid-ICI interactions in other cancer types is worth further study.